How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/secondary-malignant-neoplasm-of-stomach.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Secondary malignant neoplasm of stomach — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Secondary malignant neoplasm of stomach (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Secondary malignant neoplasm of stomach, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Herceptin	Trastuzumab-Qyyp	Roche	HER2/neu receptor antagonist monoclonal antibody	HER2 (c-erbB2) proto-oncogene transmembrane receptor protein	1998-01-01
Herceptin	trastuzumab	Roche	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01
OGIVRI	TRASTUZUMAB-DKST	MYLAN GMBH	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2
Rivoceranib	Apatinib	Zhongda Hospital		Vascular endothelial growth factor receptor 2
Herceptin	Herceptin	National Cancer Institute (NCI)		Receptor tyrosine-protein kinase erbB-2
Trastuzumab (Herceptin)	trastuzumab-herceptin	Pfizer Inc.		Receptor tyrosine-protein kinase erbB-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 2 drugs in Secondary malignant neoplasm of stomach
MYLAN GMBH · 1 drug in Secondary malignant neoplasm of stomach
National Cancer Institute (NCI) · 1 drug in Secondary malignant neoplasm of stomach
Pfizer Inc. · 1 drug in Secondary malignant neoplasm of stomach
Zhongda Hospital · 1 drug in Secondary malignant neoplasm of stomach

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Secondary malignant neoplasm of stomach:

Cite this brief

Drug Landscape (2026). Secondary malignant neoplasm of stomach — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/secondary-malignant-neoplasm-of-stomach. Accessed 2026-06-11.

Secondary malignant neoplasm of stomach full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing